Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Anaveon
Resolution Therapeutics
Purespring Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Late-stage clinical companies companies
all Clinical companies companies
Freeline Therapeutics
all Pre-clinical companies companies
Clear filters
25.10.23
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Clinical companies
Freeline Therapeutics
04.10.23
Freeline Announces Positive Initial Clinical Data
Clinical companies
Freeline Therapeutics
15.11.22
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
Operating News
Clinical companies
Freeline Therapeutics
21.07.22
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Operating News
Clinical companies
Freeline Therapeutics
10.07.22
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
Clinical companies
Freeline Therapeutics
08.02.22
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM
Clinical companies
Freeline Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Anaveon
Resolution Therapeutics
Purespring Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search